Author(s):
Hindustan Abdul Ahad, Chinthaginjala Haranath, Srikantham Sai Vikas, Naga Jyothi Varam, Tarun Ksheerasagare, Surya Prakash Reddy Gorantla
Email(s):
abdulhindustan@gmail.com
DOI:
10.5958/0974-360X.2021.00094.9 
Address:
Hindustan Abdul Ahad1*, Chinthaginjala Haranath1, Srikantham Sai Vikas2, Naga Jyothi Varam1, Tarun Ksheerasagare1, Surya Prakash Reddy Gorantla1
1Department of Industrial Pharmacy, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, Ananthapuramu – 515721, Andhra Pradesh, India.
2Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, Ananthapuramu – 515721, Andhra Pradesh, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 1,
Year - 2021
ABSTRACT:
Enzymes are the bio-molecules that are present in the various sites of the body and are specific in the organs. The recent trend of drug delivery as nanoparticles has a handful of uses. The designing of the systems in small-sized particles like nanoparticles have merits as they can easily diffuse into the membrane through the intracellular pores of very small size. Such a kind of delivery system has its applications in various treatments, one of which is in cancer therapy. Even though the anti-neoplastic drugs are much potent, they may also act on the normal cells and thus inhibiting the normal physiological process leading to serious adverse effects. Such a kind of problem can be overcome by the enzyme activated drug delivery system (EADDS). An enzyme activated system, the discharge of drugs from the system is activated by the enzymatic process. Various approaches for enzymatic drug delivery include liposomes, nanoparticles, prodrug, microparticles, etc. The main components in this system are drug, nanocarrier, promoiety, coating polymer, ligand, etc. The present review is about to provide some ideology on how the drug can be delivered to a particular type of organ or site based on the presence of respective enzyme.
Cite this article:
Hindustan Abdul Ahad, Chinthaginjala Haranath, Srikantham Sai Vikas, Naga Jyothi Varam, Tarun Ksheerasagare, Surya Prakash Reddy Gorantla. A Review on Enzyme Activated Drug Delivery System. Research J. Pharm. and Tech. 2021; 14(1):516-522. doi: 10.5958/0974-360X.2021.00094.9
Cite(Electronic):
Hindustan Abdul Ahad, Chinthaginjala Haranath, Srikantham Sai Vikas, Naga Jyothi Varam, Tarun Ksheerasagare, Surya Prakash Reddy Gorantla. A Review on Enzyme Activated Drug Delivery System. Research J. Pharm. and Tech. 2021; 14(1):516-522. doi: 10.5958/0974-360X.2021.00094.9 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-1-94
REFERENCES:
1. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nature Materials. 2013 Nov; 12(11): 991-1003.
2. Choi KY, Swierczewska M, Lee S, Chen X. Protease-activated drug development. Theranostics. 2012; 2(2):156.
3. Lopez-Otín C, Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nature Reviews Cancer. 2010 Apr; 10(4): 278.
4. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clinical Cancer Research. 2008 Mar 15; 14(6):1649-57.
5. Lopez-Otín C, Bond JS. Proteases: multifunctional enzymes in life and disease. Journal of Biological Chemistry. 2008 Nov 7; 283(45): 30433-7.
6. Yao Q, Kou L, Tu Y, Zhu L. MMP-responsive ‘smart’ drug delivery and tumor targeting. Trends in Pharmacological Sciences. 2018 Aug 1; 39(8): 766-81.
7. Yildiz T, Gu R, Zauscher S, Betancourt T. Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer. International Journal of Nanomedicine. 2018; 13: 6961.
8. Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. Advanced Drug Delivery Reviews. 2011 Jul 18; 63(8): 659-70.
9. Sun J, Yang D, Cui SH, Zhang HT, Fu Y, Wang JC, Zhang Q. Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation. International Journal of Pharmaceutics. 2019 Mar 25; 559: 48-57.
10. Chien Y. Novel drug delivery systems. CRC Press; 1991 Oct 31.
11. Thornton PD, Mart RJ, Ulijn RV. Enzyme‐responsive polymer hydrogel particles for controlled release. Advanced Materials. 2007 May 7; 19(9): 1252-6.
12. Dzamukova MR, Naumenko EA, Lvov YM, Fakhrullin RF. Enzyme-activated intracellular drug delivery with tubule clay nanoformulation. Scientific Reports. 2015 May 15; 5: 10560.
13. Bernardos A, Mondragon L, Aznar E, Marcos MD, Martinez-Manez R, Sancenon F, Soto J, Barat JM, Perez-Paya E, Guillem C, Amoros P. Enzyme-responsive intracellular controlled release using nanometric silica mesoporous supports capped with “saccharides”. Acs Nano. 2010 Oct 19; 4(11): 6353-68.
14. Yildiz T, Gu R, Zauscher S, Betancourt T. Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer. International Journal of Nanomedicine. 2018; 13: 6961.
15. Sun J, Yang D, Cui SH, Zhang HT, Fu Y, Wang JC, Zhang Q. Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation. International Journal of Pharmaceutics. 2019 Mar 25; 559: 48-57.
16. Phillips AM, Pombeiro AJ. Recent advances in organocatalytic enantioselective transfer hydrogenation. Organic & Biomolecular Chemistry. 2017; 15(11): 2307-40.
17. Yao Q, Kou L, Tu Y, Zhu L. MMP-responsive ‘smart’drug delivery and tumor targeting. Trends in Pharmacological Sciences. 2018 Aug 1; 39(8): 766-81.
18. Thornton PD, Mart RJ, Ulijn RV. Enzyme‐responsive polymer hydrogel particles for controlled release. Advanced Materials. 2007 May 7; 19(9): 1252-6.
19. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clinical Cancer Research. 2008 Mar 15; 14(6):1649-57.
20. Kam NW, O'Connell M, Wisdom JA, Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proceedings of the National Academy of Sciences. 2005 Aug 16; 102(33): 11600-5.
21. Patel K, Angelos S, Dichtel WR, Coskun A, Yang YW, Zink JI, Stoddart JF. Enzyme-responsive snap-top covered silica nanocontainers. Journal of the American Chemical Society. 2008 Feb 27; 130(8): 2382-3.
22. Ahad HA, Kumar CS, Kishore Kumar SC. Designing and evaluation of Diclofenac sodium sustained release matrix tablets using Hibiscus Rosa-Sinensis leaves mucilage. Int J of Pharm Sci Rev and Res. 2010; 1(2): 29-31.
23. Taurin S, Greish K. Enhanced vascular permeability in solid tumors: a promise for anticancer nanomedicine. In. Tight Junctions in Cancer Metastasis, Springer, Dordrecht. 2013: 81–118.
24. Colilla M, González B, Vallet-Regí M. Mesoporous silica nanoparticles for the design of smart delivery nanodevices. Biomaterials Science. 2013; 1(2): 114-34.
25. Wan Q, Xie L, Gao L, Wang Z, Nan X, Lei H, Long X, Chen ZY, He CY, Liu G, Liu X. Self-assembled magnetic theranostic nanoparticles for highly sensitive MRI of minicircle DNA delivery. Nanoscale. 2013; 5(2): 744-52.
26. Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Molecular Pharmaceutics. 2010 Oct 6; 7(6): 1899-912.
27. Bolognesi ML, Gandini A, Prati F, Uliassi E. From companion diagnostics to theranostics: a new avenue for alzheimer’s disease? Miniperspective. Journal of Medicinal Chemistry. 2016 May 6; 59(17): 7759-70.
28. Aulić S, Bolognesi ML, Legname G. Small-molecule theranostic probes: a promising future in neurodegenerative diseases. International Journal of Cell Biology. 2013; 2013.
29. McCarthy JR. Multifunctional agents for concurrent imaging and therapy in cardiovascular disease. Advanced Drug Delivery Reviews. 2010 Aug 30; 62(11): 1023-30.
30. Singh AV, Khare M, Gade WN, Zamboni P. Theranostic implications of nanotechnology in multiple sclerosis: a future perspective. Autoimmune Diseases. 2012: 6; 1–12.
31. Howell M, Wang C, Mahmoud A, Hellermann G, Mohapatra SS, Mohapatra S. Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseases. Drug Delivery and Translational Research. 2013 Aug 1; 3(4): 352-63.
32. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Advanced drug delivery reviews. 2010 Aug 30; 62(11): 1064-79.
33. Joo KI, Xiao L, Liu S, Liu Y, Lee CL, Conti PS, Wong MK, Li Z, Wang P. Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. Biomaterials. 2013 Apr 1;34(12): 3098-109.
34. Gabizon AA. Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects. Journal of Drug Targeting. 2002 Jan 1; 10(7): 535-8.
35. May JP, Undzys E, Roy A, Li SD. Synthesis of a gemcitabine prodrug for remote loading into liposomes and improved therapeutic effect. Bioconjugate Chemistry. 2015 Dec 31; 27(1): 226-37.
36. Fu C, Liu T, Li L, Liu H, Chen D, Tang F. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials. 2013 Mar 1; 34(10): 2565-75.
37. Singh RK, Kim TH, Kim JJ, Lee EJ, Knowles JC, Kim HW. Mesoporous silica tubular nanocarriers for the delivery of therapeutic molecules. RSC Advances. 2013; 3(23): 8692-704.
38. Lvov Y, Aerov A, Fakhrullin R. Clay nanotube encapsulation for functional biocomposites. Advances in Colloid and Interface Science. 2014 May 1; 207: 189-98.
39. Lee Y, Jung GE, Cho SJ, Geckeler KE, Fuchs H. Cellular interactions of doxorubicin-loaded DNA-modified halloysite nanotubes. Nanoscale. 2013; 5(18): 8577-85.
40. Shutava TG, Fakhrullin RF, Lvov YM. Spherical and tubule nanocarriers for sustained drug release. Current Opinion in Pharmacology. 2014 Oct 1; 18: 141-8.
41. Crielaard BJ, Lammers T, Schiffelers RM, Storm G. Drug targeting systems for inflammatory disease: one for all, all for one. Journal of Controlled Release. 2012 Jul 20; 161(2): 225-34.
42. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: Design and clinical applications. Nat Rev Drug Discov, 2008: 7; 255-70.
43. Wei W, Minullina R, Abdullayev E, Fakhrullin R, Mills D, Lvov Y. Enhanced efficiency of antiseptics with sustained release from clay nanotubes. Rsc Advances. 2014; 4(1): 488-94.
44. Lvov Y, Abdullayev E. Functional polymer–clay nanotube composites with sustained release of chemical agents. Progress in Polymer Science. 2013 Oct 1; 38(10-11):1690-719.